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Eunethydis 
 
A STATEMENT OF THE ETHICAL PRINCIPLES GOVERNING THE 
RELATIONSHIP BETWEEN THE EUROPEAN GROUP FOR ADHD 
GUIDELINES, AND ITS MEMBERS, WITH COMMERCIAL FOR PROFIT 
ORGANISATIONS 
 
Preamble: The members of the Eunethydis ADHD Guidelines Group (referred to as 
Group below) are clinicians and researchers dedicated to the understanding of 
ADHD/Hyperkinetic Disorder and its effective treatment. Their role has been to 
prepare guidelines for the treatment of ADHD – three such guidelines have so far 
been published1,2,3. This clearly raises potential conflicts of interest with the 
commercial companies who develop and market treatments for ADHD.  
 
This document sets out the ethical principles governing the relations between the 
Group, and its members, and industry. This is important because many members of 
the Group have at one time or another entered into financial relations with 
pharmaceutical companies for a range of different activities including consultancy, 
advice, presentations to meetings, as well as funding for trials and other studies. The 
goal of these collaborations varies across activities but the common element for the 
Group is that they are motivated by a desire to improve the understanding of ADHD 
and its treatment and to disseminate best practice in both research and therapy.  
 
We are confident that these relations are conducted with both the highest ethical 
standards. The principles set out here are provided to ensure that this is both done and 
seen to be done.  The impetus for these guidelines comes from within the Group and 
is linked to the recognition for the need for an open and transparent basis for Group-
industry relations, especially in the light of the present concern that the 
pharmaceutical industry may be exerting a growing influence on the actions of 
researchers and clinicians in the ADHD field.   
 
Transparency and register of potential conflicts of interest: The notion of 
transparency will be the core principle upon which this statement is built. A fully 
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comprehensive register of any potential competing interests that arise out of work 
with commercial for-profit companies will be established and maintained by the chair 
of the Group. This will include a short detailed description of the activity involved as 
well as its time-frame. Examples of relevant activities include; advisory board 
membership, consultancy, presentations at company funded meetings, travel bursaries 
and conference attendance support. Both investigator initiated trials and pivotal phase 
3 and phase 4 marketing trials should be declared.  
 
Activities should be declared whether or not funds are paid directly to the individual 
or to an account within a university or other organisation. In time, these principles and 
procedures may be extended to not-for-profit organisations. At present it is not 
envisaged that these declarations will not include reference to the scale of financial 
involvement; but this will remain under review. Where confidentiality is required in 
these matters, register of competing interests should acknowledge the interaction in a 
general sense and note the company and product involved.  
 
Independence of Group decision making:   Members who have conducted trials on a 
particular product will be allowed to present data to the Group on those trials during 
the review process. However, these data will be evaluated by members of the Group 
that are independent of these involvements. In case of conflicting opinions about the 
merits of a study and the meaning of the results, members involved with a specific 
project will be excluded from making the final decision. If the situation arises (and it 
has not to date), when all members of the group are involved in a trial, then the chair 
will approach appropriately qualified experts to give their evaluation of the trial data. 
The value of independent statistical review of procedures and findings will be 
explored.  
 
Protection of Group members’ interests: In order to protect the interests of members 
of the group the following procedures will be established.  
 
(i) A register of attempts at undue influence by companies on the opinions and 
activities of Group members will be established and occasions of such will be placed 
on public record.  
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 (ii) An informal system of peer review will be established to ensure that documents 
written or talks prepared for companies and funded by them conform to these ethical 
guidelines.   
 
(iii) A record will be made of the outcome of this review. 
  
(iv) Before entering into financial arrangements with industrial interests Group 
members should make a disclosure that their conduct is regulated by the principles set 
out in this document.  
 
5. Ethical conduct of Group members: In order to ensure that for-profit-related 
activities are conducted within an ethical framework the following principles are set 
down.  
 
(i). Company funded drug trials should be undertaken by Group members only when 
there is an agreement that the full trial data will be made available to the investigators 
and there is no in principle veto on publication of data. 
 
(ii) Involvement of Group member in ghost written papers prepared by professional 
medical writers for companies is prohibited. Furthermore members performing trials 
for companies are expected to be independent in their interpretation, able to review all 
material before it is published, and responsible for the whole of a paper of which they 
are an author. They should avoid inducements that could lead to bias in reporting.  
 
(iii) When presenting data on company-funded trials the Group member must retain 
full editorial control and ensure that they operate in a completely unbiased and 
scientifically balanced way.  
 
(iv) In relation to data reviewed by the Group for published guidelines, to ensure 
consistency and to protect their interests, a spirit of collective responsibility will be 
adopted in which Group members present the agreed guidelines position. However, 
this position needs to be reconciled with the need to maintain the individual academic 
freedom of Group members and to respond to developments in the field. Where these 
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amendments to the published guideline position are made they will be reported to the 
Group.  
 
(v)  Group members conducting trials that are commercially funded (either 
investigator initiated or company sponsored) should avoid entering into  personal 
financial relations with the trial sponsor (at least until after publication of the main 
outcomes).  
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